Partner Therapeutics, Inc. — Federal Contractor Profile
Partner Therapeutics, Inc. Secures $6.18 Billion in Federal Contracts
Contractor Overview
Total Contract Value: $6,177,501,377 ($6.2B)
Total Awards: 71
Company Profile
Partner Therapeutics, Inc. is a significant federal contractor with a substantial footprint in government spending, having secured a total of $6.18 billion in contracts. The company's core capabilities and specializations are not explicitly detailed in the available data, but given the scale of their operations, it is likely that they provide a range of pharmaceutical and biotechnology services to the federal government. Their relationship with specific government agencies is not detailed, and they have not secured any recent contracts. The company's contract patterns reveal a diversified client base, with no sole-source contracts and a focus on competitive bidding. Their track record, notable projects, and performance history are not detailed, but their consistent reliance on competitive bidding suggests a strong market position. The company's business strategy appears to be centered around maintaining a diverse portfolio of contracts and leveraging competitive bidding to secure work. Partner Therapeutics, Inc. is a major player in the federal contracting space, with a strong track record of securing competitive contracts and a diversified client base.
Specializations
- Pharmaceutical Research
- Biotechnology
- Drug Development
- Clinical Trials
- Regulatory Compliance
- Pharmaceutical Manufacturing
- Therapeutic Development
- Biological Products
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 100%
Agency Concentration: moderate
Growth Trajectory: expanding
Sole Source Rate: 0%
Recompete Rate: 62%
Competitive Position
Partner Therapeutics, Inc. is a dominant player in the federal contracting space, with a strong track record of securing competitive contracts. Their consistent reliance on competitive bidding suggests a strong market position and a reputation for delivering high-quality services. However, their lack of detailed specialization and recent contract information makes it challenging to assess their specific niche within the industry.
Value to Taxpayers
Partner Therapeutics, Inc. provides significant value to taxpayers through their extensive portfolio of contracts. Their focus on competitive bidding and diverse client base suggests a strong market position and a commitment to delivering high-quality services. However, the lack of detailed information on their specific services and performance history makes it difficult to fully assess their value.
Agency Relationships
Partner Therapeutics, Inc. has a diversified client base, with no specific agencies highlighted. Their lack of detailed information on agency relationships makes it challenging to assess their dependency on any single agency. However, their consistent reliance on competitive bidding suggests a strong market position and a diversified client base.
Red Flags
- No recent contracts available, which may indicate a lack of current activity or potential issues with their business strategy.
- No sole-source contracts, which may indicate a lack of specialized capabilities or a focus on competitive bidding.
- Diversified client base, which may indicate a lack of deep relationships with specific agencies.
Green Flags
- 100% competitive win rate, indicating a strong market position and a reputation for delivering high-quality services.
- Diversified client base, indicating a strong market position and a diversified revenue stream.
- No sole-source contracts, indicating a focus on competitive bidding and a commitment to fair competition.
Key Contracts
Partner Therapeutics, Inc. has secured a total of $6.18 billion in contracts, with an average contract size of $87,007,062. While no specific recent contracts are available, their track record of securing competitive contracts suggests a strong market position and a commitment to delivering high-quality services. Their diverse portfolio of contracts indicates a strong market position and a diversified revenue stream. However, the lack of detailed information on their specific services and performance history makes it difficult to fully assess their capabilities and performance.
Frequently Asked Questions
What does PARTNER THERAPEUTICS, INC. do for the federal government?
Partner Therapeutics, Inc. is a major federal contractor with a diverse portfolio of contracts in the pharmaceutical and biotechnology sectors. They likely provide a range of services including pharmaceutical research, biotechnology, drug development, clinical trials, regulatory compliance, and therapeutic development. Their core capabilities are not explicitly detailed in the available data, but given the scale of their operations, it is likely that they provide a range of pharmaceutical and biotechnology services to the federal government.
How much taxpayer money does PARTNER THERAPEUTICS, INC. receive?
Partner Therapeutics, Inc. has secured a total of $6.18 billion in federal contracts. The average contract size is $87,007,062, indicating a significant investment in their services. Their contract patterns reveal a diversified client base and a focus on competitive bidding, suggesting a strong market position and a diversified revenue stream.
Is PARTNER THERAPEUTICS, INC. good value for taxpayer money?
Partner Therapeutics, Inc. provides significant value to taxpayers through their extensive portfolio of contracts. Their focus on competitive bidding and diverse client base suggests a strong market position and a commitment to delivering high-quality services. However, the lack of detailed information on their specific services and performance history makes it difficult to fully assess their value. Their consistent reliance on competitive bidding and diversified client base suggests a strong market position and a commitment to delivering high-quality services.
How does PARTNER THERAPEUTICS, INC. win its contracts?
Partner Therapeutics, Inc. has a strong track record of securing competitive contracts, with a 100% competitive win rate. Their consistent reliance on competitive bidding suggests a strong market position and a commitment to fair competition. Their diversified client base and lack of sole-source contracts indicate a focus on competitive bidding and a commitment to delivering high-quality services.
What agencies use PARTNER THERAPEUTICS, INC. most?
Partner Therapeutics, Inc. has a diversified client base, with no specific agencies highlighted. Their lack of detailed information on agency relationships makes it challenging to assess their dependency on any single agency. However, their consistent reliance on competitive bidding suggests a strong market position and a diversified client base.
What are the risks of relying on PARTNER THERAPEUTICS, INC.?
Partner Therapeutics, Inc. has a diversified client base and a strong track record of securing competitive contracts. However, their lack of recent contracts and detailed information on their specific services and performance history makes it difficult to fully assess their capabilities and performance. Their lack of sole-source contracts and focus on competitive bidding suggest a strong market position and a commitment to fair competition, but their diversified client base may indicate a lack of deep relationships with specific agencies.
How does PARTNER THERAPEUTICS, INC. compare to similar contractors?
Partner Therapeutics, Inc. is a major player in the federal contracting space, with a strong track record of securing competitive contracts. Their consistent reliance on competitive bidding suggests a strong market position and a commitment to delivering high-quality services. However, their lack of detailed specialization and recent contract information makes it challenging to fully assess their specific niche within the industry. They are likely one of many major players in the pharmaceutical and biotechnology sectors, with a strong market position and a diversified client base.
Recent Federal Contracts
Partner Therapeutics, Inc. has 5 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| HHS awards $99.3M for LEUKINE 250MCG VIL INJ, a significant investment in pha... | Department of Health and Human Services | $99.3M | N/A |
| HHS awards $59M for Leukine injections, a critical biodefense medication, und... | Department of Health and Human Services | $59.0M | N/A |
| HHS Spends $55M on Leukine Injections from Partner Therapeutics, Inc. | Department of Health and Human Services | $55.0M | N/A |
| HHS awarded $37.6M for Colony Stimulating Factors, with a per-unit cost 20% a... | Department of Health and Human Services | $37.6M | N/A |
| VA awards $36.3M for emergency business-critical medications, ensuring timely... | Department of Veterans Affairs | $36.3K | N/A |